Home » Teva OK’d to Begin Phase III Chronic Heart Failure Trial Using Mesoblast’s Cells
Teva OK’d to Begin Phase III Chronic Heart Failure Trial Using Mesoblast’s Cells
Teva and its partner Mesoblast have received notice of FDA approval for a Phase III trial of patients with congestive heart failure using Mesoblast’s Mesenchymal Precursor Cells.
Pharmabiz.com
Pharmabiz.com
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May